Comparison

Methyl protodioscin European Partner

Item no. TMO-T3771-5mg
Manufacturer TargetMol
CASRN 54522-52-0
Amount 5mg
Category
Type Molecules
Specific against other
Citations 1. Ma W,et al.Methyl protodioscin increases ABCA1 expression and cholesterol efflux while inhibiting gene expressions for synthesis of cholesterol and triglycerides by suppressing SREBP transcription and microRNA 33a/b levels.Atherosclerosis. 2015 Apr;239(2):566-70.
Smiles C[CH]1[CH]2[CH](C[CH]3[C]2(CC[CH]4[CH]3CC=C5[C]4(CC[CH](C5)O[CH]6C([CH]([CH]([CH](O6)CO)O[CH]7[CH]([CH]([CH]([CH](O7)C)O)O)O)O)O[CH]8[CH]([CH]([CH]([CH](O8)C)O)O)O)C)C)O[C]1(CC[CH](C)CO[CH]9[CH]([CH]([CH]([CH](O9)CO)O)O)O)OC
ECLASS 10.1 32169090
ECLASS 11.0 32169090
UNSPSC 12000000
Alias Apoptosis inducer inhibitor
Available
Bioactivity
Methyl protodioscin has antitumor property. Methyl protodioscin potentially increase HDL cholesterol while reducing LDL cholesterol and triglycerides.Methyl protodioscin induced apoptotic process in human A549 cells is closely associated with Mitochondrial membrane potential, mitochondrial cytochrome c and caspase-3
MolWt
1063, 23
Pathways
Apoptosis
Receptor
Apoptosis inducer

Note: The presented information and documents (Manual, Product Datasheet, Safety Datasheet and Certificate of Analysis) correspond to our latest update and should serve for orientational purpose only. We do not guarantee the topicality. We would kindly ask you to make a request for specific requirements, if necessary.

All products are intended for research use only (RUO). Not for human, veterinary or therapeutic use.

Amount: 5mg
Available: In stock
available

Compare

Add to wishlist

Get an offer

Request delivery time

Ask a technical question

Submit a bulk request

Questions about this Product?
 
Close